Development of a new permeability assay using low-efflux MDCKII cells.

Permeability is an important property of drug candidates. The Madin-Darby canine kidney cell line (MDCK) permeability assay is widely used and the primary concern of using MDCK cells is the presence of endogenous transporters of nonhuman origin. The canine P-glycoprotein (Pgp) can interfere with permeability and transporter studies, leading to less reliable data. A new cell line, MDCKII-LE (low efflux), has been developed by selecting a subpopulation of low-efflux cells from MDCKII-WT using an iterative fluorescence-activated cell sorting technique with calcein-AM as a Pgp and efflux substrate. MDCKII-LE cells are a subpopulation of MDCKII cells with over 200-fold lower canine Pgp mRNA level and fivefold lower protein level than MDCKII-WT. MDCKII-LE cells showed less functional efflux activity than MDCKII-WT based on efflux ratios. Notably, MDCKII-MDR1 showed about 1.5-fold decreased expression of endogenous canine Pgp, suggesting that using the net flux ratio might not completely cancel out the background endogenous transporter activities. MDCKII-LE cells offer clear advantages over the MDCKII-WT by providing less efflux transporter background signals and minimizing interference from canine Pgp. The MDCKII-LE apparent permeability values well differentiates compounds from high to medium/low human intestinal absorption and can be used for Biopharmaceutical Classification System. The MDCKII-LE permeability assay (4-in-1 cassette dosing) is high throughput with good precision, reproducibility, robustness, and cost-effective.

[1]  J. Crison,et al.  A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability , 1995, Pharmaceutical Research.

[2]  Nipa Shah,et al.  Biopharmaceutics classification system: validation and learnings of an in vitro permeability assay. , 2009, Molecular pharmaceutics.

[3]  Leslie Z. Benet,et al.  Predicting Drug Disposition via Application of BCS: Transport/Absorption/ Elimination Interplay and Development of a Biopharmaceutics Drug Disposition Classification System , 2004, Pharmaceutical Research.

[4]  Cuiping Chen,et al.  P-glycoprotein limits the brain penetration of nonsedating but not sedating H1-antagonists. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[5]  E. Duchoslav,et al.  A high-capacity LC/MS system for the bioanalysis of samples generated from plate-based metabolic screening. , 2001, Analytical chemistry.

[6]  H. Lennernäs.  Animal data: the contributions of the Ussing Chamber and perfusion systems to predicting human oral drug delivery in vivo. , 2007, Advanced drug delivery reviews.

[7]  C. Bigogno,et al.  Evaluation of in vitro brain penetration: optimized PAMPA and MDCKII-MDR1 assay comparison. , 2007, International journal of pharmaceutics.

[8]  Vinod P. Shah,et al.  Biopharmaceutics Classification System: The Scientific Basis for Biowaiver Extensions , 2002, Pharmaceutical Research.

[9]  Thomas J. Raub,et al.  Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability. , 1989, Gastroenterology.

[10]  F. Nelson,et al.  The Effect of Breast Cancer Resistance Protein and P-Glycoprotein on the Brain Penetration of Flavopiridol, Imatinib Mesylate (Gleevec), Prazosin, and 2-Methoxy-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)propanoic Acid (PF-407288) in Mice , 2009, Drug Metabolism and Disposition.

[11]  Kristina Luthman,et al.  Caco-2 monolayers in experimental and theoretical predictions of drug transport1PII of original article: S0169-409X(96)00415-2. The article was originally published in Advanced Drug Delivery Reviews 22 (1996) 67–84.1 , 2001 .

[12]  Thomas J. Raub,et al.  In vitro models of the blood-brain barrier. , 1998, Alternatives to laboratory animals : ATLA.

[13]  Alex Avdeef,et al.  Physicochemical Profiling (Solubility, Permeability and Charge State) , 2001 .

[14]  T. Friedberg,et al.  Endogenous drug transporters in in vitro and in vivo models for the prediction of drug disposition in man. , 2002, Biochemical pharmacology.

[15]  H. van de Waterbeemd,et al.  ADMET in silico modelling: towards prediction paradise? , 2003, Nature reviews. Drug discovery.

[16]  E. Kerns,et al.  High throughput physicochemical profiling for drug discovery. , 2001, Journal of pharmaceutical sciences.

[17]  C. Ehrhardt,et al.  Drug Absorption Studies: In Situ, In Vitro and In Silico Models , 2021 .

[18]  Edward H. Kerns,et al.  The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery , 2010, Nature Reviews Drug Discovery.

[19]  John Janiszewski,et al.  A centralized approach to tandem mass spectrometry method development for high-throughput ADME screening. , 2006, Rapid communications in mass spectrometry : RCM.

[20]  D. B. Duignan,et al.  A 96-well efflux assay to identify ABCG2 substrates using a stably transfected MDCK II cell line. , 2006, Molecular pharmaceutics.

[21]  K. Luthman,et al.  Caco-2 monolayers in experimental and theoretical predictions of drug transport , 1996 .

[22]  J. Polli,et al.  Rational use of in vitro P-glycoprotein assays in drug discovery. , 2001, The Journal of pharmacology and experimental therapeutics.

[23]  Wolfgang Löscher,et al.  Differences in the expression of endogenous efflux transporters in MDR1‐transfected versus wildtype cell lines affect P‐glycoprotein mediated drug transport , 2010, British journal of pharmacology.

[24]  Dennis A. Smith.  Discovery and ADMET: Where are we now. , 2011, Current topics in medicinal chemistry.

[25]  Han van de Waterbeemd,et al.  Pharmacokinetics and metabolism in drug design , 2001 .

[26]  M. Bock,et al.  Role of Mechanistic Transport Studies in Lead Optimization , 2006 .

[27]  Edward H. Kerns,et al.  Drug-like Properties: Concepts, Structure Design and Methods: from ADME to Toxicity Optimization , 2008 .

[28]  J. Tolan,et al.  MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. , 1999, Journal of pharmaceutical sciences.

[29]  Tetsuya Terasaki,et al.  Quantitative Atlas of Membrane Transporter Proteins: Development and Application of a Highly Sensitive Simultaneous LC/MS/MS Method Combined with Novel In-silico Peptide Selection Criteria , 2008, Pharmaceutical Research.

[30]  Paul W Brown,et al.  Liquid chromatography/tandem mass spectrometry based targeted proteomics quantification of P-glycoprotein in various biological samples. , 2011, Rapid communications in mass spectrometry : RCM.

[31]  Li Di,et al.  Profiling drug-like properties in discovery research. , 2003, Current opinion in chemical biology.

[32]  K Gubernator,et al.  Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes. , 1998, Journal of medicinal chemistry.

[33]  David B Duignan,et al.  High throughput ADME screening: practical considerations, impact on the portfolio and enabler of in silico ADME models. , 2008, Current drug metabolism.

[34]  B. Rothen‐Rutishauser,et al.  Cell cultures as tools in biopharmacy. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[35]  J. Hakkarainen,et al.  Comparison of in vitro cell models in predicting in vivo brain entry of drugs. , 2010, International journal of pharmaceutics.

[36]  Thomas J. Vidmar,et al.  The Madin Darby Canine Kidney (MDCK) Epithelial Cell Monolayer as a Model Cellular Transport Barrier , 2004, Pharmaceutical Research.